335 related articles for article (PubMed ID: 19635524)
1. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
2. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Toxicology; 2004 May; 197(3):253-61. PubMed ID: 15033547
[TBL] [Abstract][Full Text] [Related]
3. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
4. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
Wsól V; Szotáková B; Skálová L; Maser E
Chem Biol Interact; 2003 Feb; 143-144():459-68. PubMed ID: 12604232
[TBL] [Abstract][Full Text] [Related]
5. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
Skálová L; Wsól V; Szotáková B; Kvasnicková E
Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
[TBL] [Abstract][Full Text] [Related]
6. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
Szotáková B; Skálová L; Jílek P; Buchta V; Wsól V
J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
[TBL] [Abstract][Full Text] [Related]
7. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
Wsól V; Szotáková B; Skálová L; Cepková H; Kvasnicková E
Enantiomer; 2000; 5(3-4):263-70. PubMed ID: 11126866
[TBL] [Abstract][Full Text] [Related]
8. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
Szotáková B; Skálová L; Wsól V; Kvasniècková E
J Pharm Pharmacol; 2000 May; 52(5):495-500. PubMed ID: 10864136
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
Wsól V; Skálová L; Szotáková B; Trejtnar F; Kvasnicková E
Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
[TBL] [Abstract][Full Text] [Related]
11. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
12. Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase.
Skarka A; Skarydová L; Stambergová H; Wsól V
Chem Biol Interact; 2011 May; 191(1-3):66-74. PubMed ID: 21185270
[TBL] [Abstract][Full Text] [Related]
13. 11Beta-hydroxysteroid dehydrogenase type 1: purification from human liver and characterization as carbonyl reductase of xenobiotics.
Maser E; Wsol V; Martin HJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):34-7. PubMed ID: 16343739
[TBL] [Abstract][Full Text] [Related]
14. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily.
Skarydová L; Wsól V
Drug Metab Rev; 2012 May; 44(2):173-91. PubMed ID: 22181347
[TBL] [Abstract][Full Text] [Related]
15. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics.
Martin HJ; Breyer-Pfaff U; Wsol V; Venz S; Block S; Maser E
Drug Metab Dispos; 2006 Mar; 34(3):464-70. PubMed ID: 16381663
[TBL] [Abstract][Full Text] [Related]
16. Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand.
Skarydová L; Andrýs R; Holubová L; Stambergová H; Kňavová J; Wsól V; Bílková Z
J Sep Sci; 2013 Apr; 36(7):1176-84. PubMed ID: 23495195
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of NAD-dependent morphine 6-dehydrogenase from hamster liver cytosol, a new member of the aldo-keto reductase superfamily.
Todaka T; Yamano S; Toki S
Arch Biochem Biophys; 2000 Feb; 374(2):189-97. PubMed ID: 10666297
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
Wsól V; Szotáková B; Kvasnicková E; Fell AF
J Chromatogr A; 1998 Feb; 797(1-2):197-201. PubMed ID: 9542111
[TBL] [Abstract][Full Text] [Related]
19. Chinese hamster monomeric carbonyl reductases of the short-chain dehydrogenase/reductase superfamily.
Miura T; Nishinaka T; Takama M; Murakami M; Terada T
Chem Biol Interact; 2009 Mar; 178(1-3):110-6. PubMed ID: 18983989
[TBL] [Abstract][Full Text] [Related]
20. Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase.
Kleingeist B; Böcker R; Geisslinger G; Brugger R
J Pharm Pharm Sci; 1998; 1(1):38-46. PubMed ID: 10942971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
